Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells 6,325 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 6,325 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $69,828.00. Following the transaction, the chief executive officer now directly owns 75,869 shares in the company, valued at $837,593.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 18th, Katherine Stueland sold 8,559 shares of GeneDx stock. The stock was sold at an average price of $10.59, for a total value of $90,639.81.

GeneDx Price Performance

Shares of GeneDx stock traded up $6.07 during trading on Tuesday, reaching $17.07. 7,282,556 shares of the company’s stock were exchanged, compared to its average volume of 325,185. The firm’s 50-day moving average price is $9.39 and its 200 day moving average price is $5.09. The company has a market cap of $444.67 million, a P/E ratio of -2.25 and a beta of 2.75. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.95 and a current ratio of 3.10. GeneDx Holdings Corp. has a 1-year low of $1.16 and a 1-year high of $18.24.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, February 20th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.01. GeneDx had a negative return on equity of 49.64% and a negative net margin of 86.77%. The firm had revenue of $57.42 million during the quarter, compared to the consensus estimate of $57.00 million. As a group, research analysts anticipate that GeneDx Holdings Corp. will post -2.02 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Institutional investors have recently added to or reduced their stakes in the stock. PFG Investments LLC acquired a new position in GeneDx in the 1st quarter worth about $95,000. Decheng Capital LLC bought a new stake in shares of GeneDx during the fourth quarter worth about $285,000. Thompson Davis & CO. Inc. increased its stake in shares of GeneDx by 99.4% in the fourth quarter. Thompson Davis & CO. Inc. now owns 19,944 shares of the company’s stock valued at $55,000 after buying an additional 9,944 shares during the period. Oracle Investment Management Inc. raised its holdings in GeneDx by 14.9% in the 3rd quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock valued at $3,620,000 after buying an additional 128,731 shares during the last quarter. Finally, HighTower Advisors LLC boosted its position in GeneDx by 14.1% during the 3rd quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock worth $865,000 after buying an additional 29,361 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on WGS shares. BTIG Research increased their target price on GeneDx from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen increased their price objective on shares of GeneDx from $14.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, The Goldman Sachs Group boosted their target price on shares of GeneDx to $11.00 and gave the company a “neutral” rating in a research report on Monday, April 15th.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.